Prolia (Denosumab) and Trazodone Interaction: Safety, Risks, and Clinical Guidance

Why These Two Drugs Get Prescribed Together

Osteoporosis and insomnia or depression frequently coexist in the same patient population. Denosumab (brand name Prolia) is a subcutaneous monoclonal antibody given every six months for osteoporosis, approved by the FDA in 2010 for postmenopausal women at high fracture risk [1]. Trazodone, a serotonin antagonist and reuptake inhibitor (SARI), is prescribed for major depressive disorder and widely used off-label at low doses (25 to 100 mg) for insomnia.

A 2019 analysis of Medicare Part D claims found that approximately 28% of women aged 65 and older receiving anti-osteoporosis therapy also filled at least one prescription for a sedating psychotropic medication within the same 12-month period [2]. Sleep disturbances affect up to 50% of postmenopausal women according to data from the Study of Women's Health Across the Nation (SWAN) [3]. The overlap is common. Understanding the interaction profile matters.

Pharmacokinetic Analysis: No Metabolic Conflict

Denosumab is a fully human IgG2 monoclonal antibody. It does not pass through hepatic cytochrome P450 enzymes. The FDA prescribing information for Prolia confirms that no formal drug-drug interaction studies were conducted because monoclonal antibodies are degraded by intracellular catabolism in the reticuloendothelial system, not by CYP-mediated oxidation [1]. This means denosumab will not inhibit, induce, or compete with any CYP enzyme.

Trazodone is metabolized primarily by CYP3A4, with a minor contribution from CYP2D6 [4]. Its active metabolite, meta-chlorophenylpiperazine (mCPP), is formed through CYP3A4-mediated N-dealkylation. Strong CYP3A4 inhibitors (ritonavir, ketoconazole) can increase trazodone exposure significantly. Strong CYP3A4 inducers (carbamazepine) can reduce it. Denosumab does neither.

There is zero competition at the CYP level. No P-glycoprotein interaction exists either, since denosumab is not a Pgp substrate. The two drugs are pharmacokinetically invisible to each other.

The Real Risk: Pharmacodynamic Overlap on Fall and Fracture

The absence of a pharmacokinetic interaction does not mean the combination is risk-free. The concern is pharmacodynamic. Trazodone produces dose-dependent sedation, dizziness, and orthostatic hypotension. A meta-analysis published in the British Medical Journal found that sedating antidepressants, trazodone included, increased fall risk in older adults by 1.7-fold (OR 1.71, 95% CI 1.35 to 2.16) [5]. Falls are the proximate cause of more than 90% of hip fractures.

Patients who receive denosumab already carry elevated fracture risk by definition. Adding a medication that increases the probability of falling creates a compounding hazard. The bone is fragile. The medication makes the patient more likely to impact it. A 2017 cohort study in the Journal of Bone and Mineral Research found that concurrent use of sedating psychotropics in osteoporosis patients was associated with a 34% higher rate of non-vertebral fracture compared to osteoporosis patients not on sedating medications [6].

The American Geriatrics Society Beers Criteria (2023 update) lists trazodone among medications that should be used with caution in adults 65 and older specifically because of fall risk from sedation and orthostatic hypotension [7]. This recommendation applies regardless of what other drugs the patient takes, but the stakes are higher when bones are already compromised.

Hypocalcemia: The Denosumab-Specific Risk Trazodone Can Mask

Denosumab suppresses osteoclast activity by binding RANK ligand, which reduces bone resorption and can lower serum calcium. Hypocalcemia is listed as a serious adverse reaction on the Prolia label [1]. In the FREEDOM trial (N=7,808), clinically significant hypocalcemia occurred in approximately 2% of denosumab-treated patients [8].

Why does trazodone matter here? Symptoms of mild hypocalcemia include fatigue, muscle cramps, paresthesias, and cognitive dulling. Trazodone's sedating effects can obscure these early warning signs. A patient who feels "foggy" or fatigued may attribute it to trazodone rather than dropping calcium. This creates a masking effect that delays recognition.

Practical response: check serum calcium and 25-hydroxyvitamin D before each denosumab injection. The Prolia label mandates calcium and vitamin D supplementation in all patients. Typical supplementation is calcium 1,000 mg/day plus vitamin D 400 to 800 IU/day, though patients with baseline deficiency often require 2,000 to 4,000 IU/day of vitamin D₃ to reach a 25(OH)D level above 30 ng/mL [9].

Trazodone, Bone Metabolism, and Serotonin Signaling

The relationship between serotonin and bone is not straightforward. Peripheral serotonin (gut-derived) appears to inhibit osteoblast proliferation, while central serotonin (brain-derived) promotes bone formation through sympathetic tone reduction [10]. A study published in the New England Journal of Medicine demonstrated that gut-derived serotonin acts as a hormone that inhibits bone formation via the Lrp5 pathway [10].

Trazodone blocks postsynaptic 5-HT2A receptors and inhibits serotonin reuptake. Its net effect on bone turnover markers has not been studied in dedicated trials. SSRIs as a class have been associated with a modest increase in fracture risk (relative risk approximately 1.3 to 1.7 in observational studies), but this association is weaker and less consistent for trazodone than for SSRIs like fluoxetine or sertraline [11]. A Danish nationwide cohort study published in Osteoporosis International found that SARI-class agents carried a lower fracture risk signal than SSRIs (adjusted HR 1.12, 95% CI 0.94 to 1.33) [11].

The clinical takeaway: trazodone's direct effect on bone density is uncertain and likely small. The fall risk from sedation is a much larger contributor to fracture hazard than any theoretical effect on osteoblast biology.

Monitoring Protocol for Patients on Both Drugs

A structured approach reduces risk without requiring discontinuation of either medication.

Before starting or continuing the combination:

• Obtain serum calcium, albumin, phosphorus, and 25(OH)D levels
• Perform a Timed Up-and-Go (TUG) test or equivalent fall-risk assessment
• Review the full medication list for other sedating agents (benzodiazepines, opioids, antihistamines, gabapentinoids)
• Document trazodone dose and indication

At each denosumab injection (every 6 months):

• Recheck serum calcium and vitamin D
• Reassess fall history since last visit
• Screen for trazodone-related orthostatic symptoms (ask about dizziness on standing, nighttime falls, near-falls)
• Confirm calcium and vitamin D supplementation adherence

Ongoing:

• If trazodone dose exceeds 100 mg/day, evaluate whether sedation is disproportionate
• If the patient reports new dizziness or balance problems, obtain orthostatic vitals (supine and standing blood pressure at 1 and 3 minutes)
• If hypocalcemia is detected (corrected calcium <8.5 mg/dL), hold denosumab until calcium normalizes and investigate cause

The Endocrine Society Clinical Practice Guideline on pharmacological management of osteoporosis in postmenopausal women recommends routine calcium monitoring for all patients on denosumab and heightened vigilance when concurrent medications may obscure symptoms [12].

Dose Adjustments and Timing Considerations

No dose adjustment is necessary for either drug based solely on co-administration. Denosumab is given as a fixed 60 mg subcutaneous injection every 6 months. Trazodone dosing remains standard: 25 to 100 mg at bedtime for insomnia, or 150 to 400 mg/day in divided doses for depression.

Timing matters in a practical sense. Trazodone should be taken at bedtime to concentrate its sedating effects during sleep hours and minimize daytime drowsiness. Patients should be instructed to sit on the edge of the bed for 30 seconds before standing if they wake during the night. Simple environmental modifications (nightlights, removing loose rugs, grab bars in bathrooms) complement pharmacologic management.

One timing note specific to denosumab: if a patient develops gastrointestinal disturbance after the injection (nausea, which occurs in approximately 8% of patients per the FREEDOM extension data), and they are also taking trazodone, the combined sedation and nausea can increase the risk of a syncopal fall event in the first 24 to 48 hours post-injection [8]. Scheduling the denosumab injection on a day when the patient has home support is a reasonable precaution for older adults.

When to Consider Alternatives

Some patients may benefit from switching one of the two drugs. Consider replacing trazodone with a non-sedating alternative if the patient has:

• Two or more falls in the past 12 months
• Documented orthostatic hypotension (systolic drop ≥20 mmHg on standing)
• A TUG score exceeding 12 seconds
• Concurrent use of two or more other sedating medications

Non-sedating options for insomnia in osteoporosis patients include cognitive behavioral therapy for insomnia (CBT-I), which the American College of Physicians recommends as first-line therapy [13]. Melatonin (0.5 to 3 mg) carries less orthostatic and sedation risk than trazodone, though evidence of efficacy is modest.

For depression specifically, bupropion has no serotonergic sedation and does not carry the fall-risk signal seen with trazodone. A switch requires weighing the psychiatric indication against the orthopedic risk, a conversation that benefits from both the prescribing psychiatrist and the osteoporosis-managing clinician.

Discontinuing denosumab carries its own hazard. The FDA issued a Drug Safety Communication in 2022 warning that stopping Prolia leads to a rapid rebound in bone turnover and increased risk of multiple vertebral fractures, particularly within 7 months of the missed dose [14]. Replacing denosumab should be done only with a planned transition to an alternative antiresorptive (typically alendronate or zoledronic acid), not by simply stopping.

Counseling Points for Patients

Direct patient education reduces adverse events. Five specific instructions to deliver:

1. Take trazodone only at bedtime. Do not take it during the day unless your psychiatrist specifically directs you to.
2. Rise slowly. Sit up for at least 30 seconds before standing, especially at night. Orthostatic drops peak 1 to 3 hours after trazodone dosing.
3. Take your calcium and vitamin D every day. Prolia works best and is safest when calcium levels stay normal. Do not skip supplements.
4. Report new symptoms. Muscle cramps, tingling in fingers or around the mouth, unusual fatigue, or confusion could signal low calcium. Do not assume it is just the trazodone.
5. Do not stop Prolia on your own. Missing a scheduled injection can cause rapid bone loss. If you have concerns, call your prescriber before skipping a dose.

Serum calcium should be rechecked within 14 days of a denosumab injection in any patient whose pre-injection 25(OH)D was below 20 ng/mL, regardless of supplementation status [12].